Zai Lab Stock Performance
| ZLAB Stock | USD 28.09 1.66 6.28% |
On a scale of 0 to 100, Zai Lab holds a performance score of 13. The firm maintains a market beta of 0.81, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Zai Lab's returns are expected to increase less than the market. However, during the bear market, the loss of holding Zai Lab is expected to be smaller as well. Please check Zai Lab's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Zai Lab's historical returns will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Zai Lab are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Zai Lab sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.38) | Five Day Return 3.04 | Year To Date Return 4.14 | Ten Year Return (2.83) | All Time Return (2.83) |
1 | Disposition of 2500 shares by Gaynor Richard of Zai Lab at 19.5 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 845 shares by Yajing Chen of Zai Lab at 15.673 subject to Rule 16b-3 | 09/11/2024 |
3 | Disposition of 920 shares by Yajing Chen of Zai Lab subject to Rule 16b-3 | 10/01/2024 |
4 | Disposition of 301 shares by Yajing Chen of Zai Lab at 25.398 subject to Rule 16b-3 | 10/02/2024 |
5 | Disposition of 7145 shares by Joshua Smiley of Zai Lab subject to Rule 16b-3 | 10/11/2024 |
6 | Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 | 10/16/2024 |
7 | Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China | 10/29/2024 |
8 | Disposition of 500 shares by Yajing Chen of Zai Lab subject to Rule 16b-3 | 11/01/2024 |
9 | Disposition of 167 shares by Yajing Chen of Zai Lab at 30.662 subject to Rule 16b-3 | 11/04/2024 |
10 | Zai Lab gets expanded Chinese approval for Vyvgart Hytrulo | 11/11/2024 |
11 | Zai Lab Ltd Reports Q3 2024 Earnings EPS Loss of 0.04, Revenue at 101. ... | 11/12/2024 |
12 | Zai Lab Announces Proposed Public Offering of American Depositary Shares | 11/13/2024 |
13 | Janus Henderson Groups Strategic Acquisition of Zai Lab Shares | 11/14/2024 |
14 | The Zai Lab Limited Third-Quarter Results Are Out And Analysts Have Published New Forecasts | 11/15/2024 |
15 | Zai Lab Ltd Awards Stock Units to Boost Employee Incentives - TipRanks | 11/19/2024 |
16 | Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO | 11/21/2024 |
| Begin Period Cash Flow | 1 B |
Zai |
Zai Lab Relative Risk vs. Return Landscape
If you would invest 1,876 in Zai Lab on August 28, 2024 and sell it today you would earn a total of 933.00 from holding Zai Lab or generate 49.73% return on investment over 90 days. Zai Lab is currently generating 0.714% in daily expected returns and assumes 4.0844% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Zai, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zai Lab Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zai Lab's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zai Lab, and traders can use it to determine the average amount a Zai Lab's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1748
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ZLAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.08 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.71 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Zai Lab is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zai Lab by adding it to a well-diversified portfolio.
Zai Lab Fundamentals Growth
Zai Stock prices reflect investors' perceptions of the future prospects and financial health of Zai Lab, and Zai Lab fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zai Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.66) % | ||||
| Current Valuation | 2.24 B | ||||
| Shares Outstanding | 107.45 M | ||||
| Price To Book | 4.25 X | ||||
| Price To Sales | 8.48 X | ||||
| Revenue | 266.72 M | ||||
| Gross Profit | (145.39 M) | ||||
| EBITDA | (366.57 M) | ||||
| Net Income | (334.62 M) | ||||
| Cash And Equivalents | 1.26 B | ||||
| Cash Per Share | 13.10 X | ||||
| Total Debt | 15.15 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.91 X | ||||
| Book Value Per Share | 6.80 X | ||||
| Cash Flow From Operations | (198.18 M) | ||||
| Earnings Per Share | (2.80) X | ||||
| Market Capitalization | 3.02 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | (2.2 B) | ||||
| Working Capital | 736.54 M | ||||
About Zai Lab Performance
By analyzing Zai Lab's fundamental ratios, stakeholders can gain valuable insights into Zai Lab's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zai Lab has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zai Lab has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 170.76 | 249.78 | |
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.42) | (0.40) |
Things to note about Zai Lab performance evaluation
Checking the ongoing alerts about Zai Lab for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zai Lab help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zai Lab appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (334.62 M) with loss before overhead, payroll, taxes, and interest of (145.39 M). | |
| Zai Lab currently holds about 1.26 B in cash with (198.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.1. | |
| Latest headline from businesswire.com: Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO |
- Analyzing Zai Lab's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zai Lab's stock is overvalued or undervalued compared to its peers.
- Examining Zai Lab's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zai Lab's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zai Lab's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zai Lab's stock. These opinions can provide insight into Zai Lab's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zai Stock analysis
When running Zai Lab's price analysis, check to measure Zai Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zai Lab is operating at the current time. Most of Zai Lab's value examination focuses on studying past and present price action to predict the probability of Zai Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zai Lab's price. Additionally, you may evaluate how the addition of Zai Lab to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |